• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Articles by Marie Powers

Horizon Pharma Lowers its IPO Sights, Prices at $9/Share

July 29, 2011
By Marie Powers
Horizon Pharma Inc. had its eye fixed on raising $86 million in its initial public offering (IPO), but – like other biotechs this year – had to lower its horizons considerably. The Northbrook, Ill.-based company priced 5.5 million shares of common stock at $9 per share to raise $49.5 million – a 42 percent discount off the aggregate proceeds sought in the company's S-1 filing last year. (See BioWorld Today, Aug. 5, 2010.)
Read More

Heplisav Data Disappoint; Dynavax Stock Sinks 19%

July 21, 2011
By Marie Powers
Dynavax Technologies Corp. reported Wednesday that top-line data from the Phase III trial comparing its investigational hepatitis B vaccine Heplisav met all three clinical endpoints, demonstrating noninferiority, superiority and safety in comparison to the marketed hep B vaccine Engerix-B (GlaxoSmithKline). Nevertheless, investors failed to respond with enthusiasm, perhaps reflecting nervousness about a second piece of news regarding the company's consistency analysis of manufacturing data.
Read More

NewCo News: Madeira Seeks to Fill Pediatric Niche with Reformulation Plan

July 13, 2011
By Marie Powers
Reformulations aren't exactly a novel proposition in the biotech world, but Madeira Therapeutics LLC is taking that strategy one step further. The company is one of the few biotechs focused on repositioning adult compounds for the pediatric market.
Read More

NewCo News: DLVR Hopes to 'Deliver' on siRNA Potential in Cancer

July 11, 2011
By Marie Powers
A bevy of U.S.-based firms – notably Alnylam Pharmaceuticals Inc., of Cambridge, Mass. – together with London-based Silence Therapeutics plc and, more recently, South Korean start-up BioMolecular Therapeutics, have been striving mightily to become first to market using RNAi-based platform technology to treat cancer.
Read More

NewCo News: TORCell Takes Aim at AML Using Cancer-Killing T Cells

July 8, 2011
By Marie Powers
Serious conditions attract serious attention. Acute myeloid leukemia (AML) is a devastating form of cancer with a poor prognosis and limited treatment options. Already, a raft of biotechs has thrown resources at the disease, but with more failure than success. Now, TORCell Therapeutics Inc., a biotech spun out of the Ontario Institute for Cancer Research (OICR) in Toronto, is taking aim at AML with a technology to boost a patient's own double-negative T cells (DNT) – a subpopulation of T lymphocytes that has potent anticancer properties, but comprises only 1 percent of a patient's peripheral blood mononuclear cells.
Read More

Rib-X, Sanofi Ink Potential $760M Pact to Develop RX-04

July 7, 2011
By Marie Powers
Rib-X Pharmaceuticals Inc. hooked a big fish for its first partnership, inking an exclusive worldwide research collaboration and licensing option with Sanofi SA, of Paris, for antibiotics resulting from its RX-04 program for the treatment of resistant Gram-positive and resistant Gram-negative pathogens.
Read More

ODAC Votes Against Avastin for Metastatic Breast Cancer

June 30, 2011
By Marie Powers
Genentech Inc. came out fighting during the second day of the FDA's public hearing on its proposal to withdraw accelerated approval of Avastin (bevacizumab) for metastatic breast cancer, putting members of the Oncologic Drugs Advisory Committee and representatives from the Center for Drug Evaluation and Research on notice that the company wouldn't go away quietly.
Read More

Day 1 of Avastin Hearing Brings Emotional Anecdotes, Hard Facts

June 29, 2011
By Marie Powers
A parade of three dozen physicians, nurses, patients, advocates and family members overwhelmingly endorsed the continued availability of Avastin (bevacizumab) for metastatic breast cancer during the first day of the FDA's unprecedented hearing on its proposal to withdraw the drug's approval for the indication. But in a slew of legal and scientific data, representatives from the FDA's Office of New Drugs and Center for Drug Evaluation and Research laid the groundwork for an unflinching rejection of the request by Genentech Inc., of South San Francisco, and parent company Roche AG, of Basel, Switzerland, to continue marketing the drug for metastatic breast cancer while Genentech pursues new studies to support Avastin's use in the indication.
Read More

NewCo News: MingSight to Offer 'Bright' Solution for Diabetic Eye Disease

June 15, 2011
By Marie Powers
Using technology acquired from Pfizer Inc., San Diego-based biotech MingSight Pharmaceuticals Inc. has its eye on an oral therapy for retinal diseases.
Read More

NewCo News: Spring Bank Targets Hepatitis B Market with Small-Molecule Tech

June 3, 2011
By Marie Powers
A small biotech that has flown under the radar for nearly a decade may be poised to make an impact in the global hepatitis B space. Spring Bank Pharmaceuticals Inc. expects to file an investigational new drug (IND) application with the FDA this year for SB 9200, an orally bioavailable hepatitis B drug based on the company's small molecule nucleic acid hybrid (SMNH) technology.
Read More
Previous 1 2 … 160 161 162 163 164 165 166 167 168 169 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe